Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$8.84 USD
-0.68 (-7.14%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $8.84 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
Zentalis Pharmaceuticals, Inc. [ZNTL]
Reports for Purchase
Showing records 21 - 40 ( 71 total )
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Key Decisions and Key Data Coming Up
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Rich Catalyst Calendar For Azenosertib (ZN-c3), Holds More Value Than Apparent; Reit Buy and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; ZN-c3 (Azenosertib) Strategy Update Ahead
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initial Look at Osteosarcoma Data; Encouraging Efficacy and Safety
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; ZN-c3 Dose-Optimization; Biomarker-Directed Study Focuses
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ZN-c3 Continues its Assault on Oncology, with New Cyclin E Driven OC Biomarker Strategy; Reit. Buy and $55 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Reports of the Death of Synthetic Lethality are Grossly Exaggerated
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Operational Update Puts ZN-c3 and ZN-d5 in the Spotlight; Reit. Buy and Lower PT to $55 from $120
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Focus Firmly on Wee1 and BCL-2 inhibitors
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Investors Pushback on ZN-c3?s Safety Profile at AACR 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; R&D Day Details New Opportunities, New Degrader Program
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Zentalis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Catalyst-Rich 2022 Aims to Showcase the Versatility of ZN-c3 and Others; Reit. Buy and $120 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A